Gongwin Biopharm Holdings Co., Ltd.'s subsidiary Gongwin Pharmaceutical Technology Co., Ltd. received a letter from Taiwan?s Ministry of Health and Welfare, agreeing that Taiwan Gongwin will provide ?PTS100 (Para-Toluenesulfonamide, P-TSA) 330mg/mL, 5mL/amp,10amp/box? is for use by patients with oral cancer. This treatment is a compassionate treatment jointly performed by company and Chang Gung Memorial Medical Foundation Linkou Chang Gung Memorial Hospital,and is provided to Chang Gung Memorial Medical Foundation Linkou Chang Gung Memorial Hospital for treatment.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
147 TWD | 0.00% |
|
-8.12% | -20.33% |
1st Jan change | Capi. | |
---|---|---|
-20.33% | 513M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- 6617 Stock
- News Gongwin Biopharm Holdings Co., Ltd.
- Gongwin Biopharm Holdings Co., Ltd.' Subsidiary Gongwin Pharmaceutical Technology Co., Ltd. Receives Letter from Taiwan?s Ministry of Health and Welfare Approving New Drug PTS100 for the Compassionate Treatment